Néevo®/NéevoDHA® P.L.U.S. Program (Progress Through Learning, Understand & Support)
|ClinicalTrials.gov Identifier: NCT01358552|
Recruitment Status : Terminated (Insufficient number of participants)
First Posted : May 23, 2011
Last Update Posted : May 1, 2013
|Condition or disease||Intervention/treatment|
|Pregnancy||Other: Néevo®/ NéevoDHA®|
|Study Type :||Observational|
|Actual Enrollment :||53 participants|
|Official Title:||Néevo®/NéevoDHA® P.L.U.S. Program (Progress Through Learning, Understand & Support)|
|Study Start Date :||January 2011|
|Actual Primary Completion Date :||March 2012|
|Actual Study Completion Date :||March 2012|
Subjects who have been prescribed Néevo/NéevoDHA® daily.
Other: Néevo®/ NéevoDHA®
Néevo®/NéevoDHA® is an orally administered medical food indicated for the dietary management of impaired metabolic processes in women under a doctor's care who face high to intermediate risk pregnancies and are unable to fully metabolize or absorb folic acid. Néevo®/ NéevoDHA® contains L-methylfolate, the biologically active and immediately bioavailable form of folate.
- To determine the safety and tolerability of Néevo®/NéevoDHA® as measured by side effects and compliance [ Time Frame: Week 4 ]To collect data from patient surveys on the patient utilization and effectiveness of Néevo®/NéevoDHA® in a "real world" setting.
- To determine overall patient satisfaction with Néevo®/NéevoDHA® using a 9-point satisfaction scale [ Time Frame: Week 4 ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01358552
|United States, Texas|
|Noe Lira, M.D.|
|Corpus Christi, Texas, United States, 78411|
|Principal Investigator:||Noe Lira, M.D.||Noe Lira, M.D.|